Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CORT | CLUSTER | neutral | 3/10 | Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a total of $6.91M in ope | Jun 4, 2026 |
| BGMSP | 425 | bearish | 7/10 | Bio Green Med Solution, Inc. (BGMS) filed a Form 425 prospectus containing the full Business Combination Agreement (BCA) | Jun 4, 2026 |
| BGMSP | 8-K | bearish | 7/10 | Bio Green Med Solution, Inc. (BGMS) entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd., a Mal | Jun 4, 2026 |
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved routine items incl | Jun 4, 2026 |
| BMRA | 8-K | neutral | 4/10 | Biomerica entered into a Securities Purchase Agreement to sell its 6% stake (78,750 shares) in Diagnosis S.A. to buyers | Jun 4, 2026 |
| ENSCW | S-3 | bearish | 6/10 | Ensysce Biosciences filed an S-3 registration statement to register 1,300,000 shares of common stock for resale by selli | Jun 4, 2026 |
| LIXT | 424B5 | bearish | 6/10 | Lixte Biotechnology is raising approximately $16.6 million in gross proceeds through a registered direct offering of 2,3 | Jun 4, 2026 |
| FATE | 8-K | neutral | 4/10 | Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli | Jun 4, 2026 |
| XERS | 144 | neutral | 2/10 | Director Dawn Halkuff filed a Form 144 notice of intent to sell 20,000 shares of Xeris Biopharma common stock, with an e | Jun 4, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and CFO James Edgemond executed derivative exercises and sold a combined ~$1.0M in open-market sha | Jun 4, 2026 |
| SRPT | 8-K | neutral | 3/10 | Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 2026 Equity Incentive P | Jun 4, 2026 |
| CANF | 6-K | neutral | 2/10 | Can-Fite BioPharma reported that its Annual General Meeting of Shareholders held on June 4, 2026, approved all five prop | Jun 4, 2026 |
| BMRN | 8-K | neutral | 2/10 | BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders approved all four pro | Jun 4, 2026 |
| ANTX | 8-K | bullish | 7/10 | AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. A 28 | Jun 4, 2026 |
| BGMS | PRESS-RELEASE | neutral | 5/10 | BGMS announced an all-stock business combination with Future NRG Sdn. Bhd., a Malaysia-based medical waste treatment com | Jun 4, 2026 |
| LYEL | PRESS-RELEASE | neutral | 3/10 | Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 | Jun 4, 2026 |
| ZSQR | 8-K | bearish | 6/10 | Z Squared Inc. (ZSQR) entered a $50M committed equity forward purchase agreement with LucentHash / Data Part Capital, a | Jun 4, 2026 |
| SNDX | PRESS-RELEASE | neutral | 2/10 | Syndax Pharmaceuticals granted inducement awards for 66,700 shares to four new employees under the 2023 Inducement Plan. | Jun 4, 2026 |
| QUCY | S-3 | bearish | 7/10 | Quantum Cyber N.V. filed a universal shelf registration statement on Form S-3 to register up to $250,000,000 in securiti | Jun 4, 2026 |
| AMRN | COURT-RULING | bearish | 7/10 | The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a claim for induced infr | Jun 4, 2026 |
| PCRX | 144 | neutral | 2/10 | Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, value | Jun 4, 2026 |
| ALVOW | 6-K | bullish | 6/10 | Alvotech resubmitted U.S. Biologics License Applications for AVT05 (biosimilar to Simponi/Simponi Aria) and AVT06 (biosi | Jun 4, 2026 |
| SCLX | PRESS-RELEASE | neutral | 4/10 | Scilex announced a June 15, 2026 payment date for its previously declared dividend of Semnur Pharmaceuticals (OTC: SMNR) | Jun 4, 2026 |
| AIM | 8-K | neutral | 3/10 | AIM ImmunoTech released a video presentation and investor slide deck discussing previously published preclinical data on | Jun 4, 2026 |
| LPCN | 8-K | neutral | 3/10 | Lipocine filed an 8-K announcing a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression a | Jun 4, 2026 |
| EXOZ | 424B5 | bearish | 7/10 | EXOZ is conducting a dilutive public offering of common stock and warrants under its $50M shelf registration. The offeri | Jun 4, 2026 |
| PRNAF | 6-K | neutral | 3/10 | Alterity Therapeutics filed a 6-K confirming a 1-for-50 reverse share consolidation, effective June 3, 2026, with tempor | Jun 4, 2026 |
| SNDX | DEFA14A | neutral | 4/10 | Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vote FOR Proposal No. | Jun 4, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 5/10 | TOMI Environmental Solutions announced a signed purchase order for a custom SteraMist Hybrid system from a food producer | Jun 4, 2026 |
| VERU | 8-K | bullish | 6/10 | Veru Inc. entered a clinical supply agreement with Novo Nordisk under which Novo Nordisk will supply Wegovy (semaglutide | Jun 4, 2026 |